文献速递腹部儿科影像CT

一种预测切除后肝母细胞瘤预后的新型视觉模型:多中心研究

A Novel Visual Model for Predicting Prognosis of Resected Hepatoblastoma: A Multicenter Study.
PubMed 文献 · Acad Radiol · 2025-03-26

该多中心研究纳入三个中心224例肝母细胞瘤患者,从增强CT提取视觉特征并用LASSO Cox回归建模,构建视觉评分DINOv2_score、临床评分及二者联合模型。联合模型在训练和验证队列中预测无病生存和总生存的C-index均较高,校准曲线一致性好,决策曲线分析显示联合模型净获益优于单一模型。

要点

  • 基于增强CT的视觉评分DINOv2_score被识别为肝母细胞瘤关键预后指标。
  • 联合模型预测无病生存C-index训练队列0.886、验证队列0.873。
  • 联合模型预测总生存C-index训练队列0.887、验证队列0.882。

核心结论

  • 基于增强CT的视觉模型可作为预测肝母细胞瘤患者术后预后的有效工具。
  • 整合DINOv2_score与临床危险因素的联合模型在生存预测中表现更优,可为个体化治疗策略提供更精准指导。

研究设计与样本

  • 多中心研究,共分析三个中心224例患者,训练队列178例,验证队列46例。
  • 从增强CT图像提取视觉特征,采用LASSO Cox回归筛选关键特征及临床病理数据。
  • 构建视觉模型(DINOv2_score)、临床模型(Clinical_score)及整合DINOv2_score与临床危险因素的联合模型,并制作列线图。
  • 采用校准曲线和决策曲线分析(DCA)评估模型性能。

诊断标准与关键数值

  • DINOv2_score被识别为肝母细胞瘤的关键预后指标。
  • 联合模型预测无病生存的C-index(95% CI):训练队列0.886(0.879-0.895),验证队列0.873(0.837-0.909)。
  • 联合模型预测总生存的C-index(95% CI):训练队列0.887(0.877-0.897),验证队列0.882(0.858-0.906)。
  • 校准曲线显示预测结局与观察结局高度一致。
  • DCA显示在较宽阈值概率范围内,联合模型提供的临床净获益大于单独临床模型或视觉模型。

临床应用与阅片要点

  • 原文结论认为基于增强CT的视觉模型可作为预测肝母细胞瘤术后预后的有效工具。
  • 原文结论认为联合模型在生存预测中表现更优,可为个体化治疗策略提供更精准指导。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: This study aimed to evaluate the application of a contrast-enhanced CT-based visual model in predicting postoperative prognosis in patients with hepatoblastoma (HB).

MATERIALS AND METHODS: We analyzed data from 224 patients across three centers (178 in the training cohort, 46 in the validation cohort). Visual features were extracted from contrast-enhanced CT images, and key features, along with clinicopathological data, were identified using LASSO Cox regression. Visual (DINOv2_score) and clinical (Clinical_score) models were developed, and a combined model integrating DINOv2_score and clinical risk factors was constructed. Nomograms were created for personalized risk assessment, with calibration curves and decision curve analysis (DCA) used to evaluate model performance.

RESULTS: The DINOv2_score was recognized as a key prognostic indicator for HB. In both the training and validation cohorts, the combined model demonstrated superior performance in predicting disease-free survival (DFS) [C-index (95% CI): 0.886 (0.879-0.895) and 0.873 (0.837-0.909), respectively] and overall survival (OS) [C-index (95% CI): 0.887 (0.877-0.897) and 0.882 (0.858-0.906), respectively]. Calibration curves showed strong alignment between predicted and observed outcomes, while DCA demonstrated that the combined model provided greater clinical net benefit than the clinical or visual models alone across a range of threshold probabilities.

CONCLUSION: The contrast-enhanced CT-based visual model serves as an effective tool for predicting postoperative prognosis in HB patients. The combined model, integrating the DINOv2_score and clinical risk factors, demonstrated superior performance in survival prediction, offering more precise guidance for personalized treatment strategies.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. He Y, An C, Dong K, et al. A Novel Visual Model for Predicting Prognosis of Resected Hepatoblastoma: A Multicenter Study. Acad Radiol. 2025. PMID: 40140274. doi:10.1016/j.acra.2025.03.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。